Key Points
- BioNTech CEO Ugur Sahin sold 36,000 shares at an average price of $97.78, generating about $3.52 million. The transaction was executed under a pre-arranged Rule 10b5-1 plan, leaving him with 708,709 shares.
- Sahin has sold 149,500 shares for approximately $15.1 million across several transactions since September 3, potentially creating an investor overhang despite the planned nature of the sales.
- BioNTech shares opened near $98, while the company recently reported weaker-than-expected quarterly results, including a $2.53 loss per share and revenue down 59.5% year over year. Analysts nonetheless maintain a consensus “Moderate Buy” rating with a $126 price target.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 36,000 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00. Following the completion of the transaction, the chief executive officer directly owned 708,709 shares in the company, valued at $69,297,566.02. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
- On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
- On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.
BioNTech Trading Down 0.5%
Shares of NASDAQ:BNTX opened at $98.13 on Thursday. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market cap of $24.82 billion, a PE ratio of -12.53 and a beta of 1.29. The business has a 50 day moving average of $97.02 and a 200-day moving average of $95.46. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech's revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.60) EPS. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.
Hedge Funds Weigh In On BioNTech
A number of hedge funds have recently added to or reduced their stakes in the stock. Flossbach Von Storch SE acquired a new position in BioNTech in the 2nd quarter valued at $207,142,000. BNP Paribas Financial Markets increased its position in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock worth $150,235,000 after purchasing an additional 474,796 shares during the period. Bank of America Corp DE increased its position in shares of BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock worth $80,261,000 after purchasing an additional 166,432 shares during the period. GSK plc acquired a new position in BioNTech in the fourth quarter valued at about $84,711,000. Finally, First Trust Advisors LP raised its stake in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Institutional investors own 15.52% of the company's stock.
Key BioNTech News
Here are the key news stories impacting BioNTech this week:
- Positive Sentiment: Analyst views remain broadly favorable despite some disagreement. BioNTech has a consensus “Moderate Buy” rating and an average price target of $126, above recent trading levels, with several firms maintaining Buy ratings. Analysts Have Conflicting Sentiments on These Healthcare Companies
- Neutral Sentiment: CEO Ugur Sahin’s recent transactions were made under pre-arranged trading plans rather than in response to newly disclosed business developments. Institutional ownership also remains present, with several large investors increasing their positions, though institutional investors hold only about 15.5% of the stock. BioNTech SEC Form 4 Filing
- Negative Sentiment: BMO Capital Markets downgraded BioNTech from “outperform” to “market perform” and cut its price target from $128 to $105. The reduced target narrows the perceived upside and is the clearest immediate explanation for the stock’s decline. BioNTech Shares Fall After BMO Downgrade and Price Target Cut
- Negative Sentiment: Sahin sold a combined 149,500 shares from September 3 through September 9 for approximately $15.1 million, reducing his holdings in successive transactions. Although the trades were planned in advance, repeated CEO selling can create an overhang and reinforce cautious investor sentiment. BioNTech CEO Insider Selling
Analyst Upgrades and Downgrades
BNTX has been the topic of a number of research reports. UBS Group raised BioNTech from a "neutral" rating to a "buy" rating and upped their price objective for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Citigroup reduced their target price on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. Wall Street Zen downgraded shares of BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioNTech in a research report on Monday, July 6th. Finally, Morgan Stanley dropped their price objective on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating for the company in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioNTech presently has an average rating of "Moderate Buy" and a consensus target price of $126.00.
Check Out Our Latest Stock Analysis on BioNTech
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.
The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.
BioNTech was founded in 2008 and is headquartered in Mainz, Germany.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
